Report Outline

VIEW
CATALYST
SUMMARY
ANALYSIS
Thriving in turbulent times requires streamlining operations
Restructuring and layoffs remain core tactics to streamline operations
Innovative sales and marketing strategies are necessary for companies to survive
Outsourcing will become more mainstream as companies become leaner
Biotech and biomedical research will play a key role in shaping the future of the industry
Joint ventures and mergers and acquisitions between pharma and biotech will continue well into 2009
Stem cell and biomedical research will flourish under Barack Obama's new administration
Uncertainty looms for small biotech companies amidst the current financial crisis
Pharma companies turn to the emerging markets to remain competitive on a global scale
Generic drugs secure India and China's dominance in the global pharmaceutical market
ACTIONS
Impact on the life science industry
Improving R&D and increasing innovation are of the utmost importance
Pharma companies must embrace biotechnology to survive during these turbulent times
A change in pharmaceutical sales and marketing strategies must take place to target all stakeholders
Recommendations for technology vendors serving the life science industry
IT solutions must optimize life science business processes
Vendors need to be flexible to cater to the life science industry in the emerging markets
IT vendors must educate companies on the benefits of pharma-specific commercial IT solutions

APPENDIX

Definitions and Abbreviations
Methodology
Further reading
Ask the analyst
consulting
Disclaimer

List of Figures

Figure 1: The pharmaceutical industry faces many challenges and has a long, difficult road ahead
Figure 2: The long and costly drug discovery and development process
Figure 3: Pharma companies continue to announce big layoffs, but now the mid-market enters the game
Figure 4: Adoption level of SCM solutions in China and India
Figure 5: IT budget allocation for R&D and non-R&D processes in China and India